Monaco Asset Management SAM Has $169,000 Holdings in Q32 Bio Inc. $QTTB

Monaco Asset Management SAM cut its holdings in Q32 Bio Inc. (NASDAQ:QTTB) by 83.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,919 shares of the company’s stock after selling 260,218 shares during the period. Monaco Asset Management SAM’s holdings in Q32 Bio were worth $169,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of QTTB. AQR Capital Management LLC acquired a new position in shares of Q32 Bio in the first quarter valued at about $68,000. Goldman Sachs Group Inc. grew its stake in Q32 Bio by 140.9% during the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after buying an additional 25,953 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Q32 Bio during the first quarter worth about $50,000. Marshall Wace LLP acquired a new stake in Q32 Bio during the second quarter worth about $25,000. Finally, Jane Street Group LLC acquired a new stake in Q32 Bio during the second quarter worth about $69,000. 31.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Q32 Bio in a research note on Tuesday, May 5th. Zacks Research downgraded shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Mizuho assumed coverage on shares of Q32 Bio in a research note on Friday, May 22nd. They set an “outperform” rating and a $14.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Q32 Bio in a research note on Monday, May 18th. They set an “overweight” rating on the stock. Three investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Q32 Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Q32 Bio Price Performance

Shares of NASDAQ QTTB opened at $11.05 on Monday. The company has a 50 day simple moving average of $6.35 and a 200 day simple moving average of $4.66. The firm has a market cap of $187.41 million, a PE ratio of 4.15 and a beta of 0.26. Q32 Bio Inc. has a 1 year low of $1.35 and a 1 year high of $13.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.36 and a quick ratio of 5.36.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. On average, research analysts forecast that Q32 Bio Inc. will post -1.96 EPS for the current year.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.